Sentiment-Signal
17,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Nuvalent, Inc. |
|---|---|
| Ticker | NUVL |
| CIK | 0001861560 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 7,30 Mrd. USD |
| Beta | 1,31 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -425,377,000 | -5.85 | 1,412,705,000 | 1,248,339,000 | |
| 2025-09-30 | 10-Q | -122,437,000 | -1.70 | 979,910,000 | 845,399,000 | |
| 2025-06-30 | 10-Q | -99,653,000 | -1.39 | 1,040,543,000 | 939,742,000 | |
| 2025-03-31 | 10-Q | -84,582,000 | -1.18 | 1,105,806,000 | 1,011,057,000 | |
| 2024-12-31 | 10-K | -260,756,000 | -3.93 | 1,141,752,000 | 1,069,792,000 | |
| 2024-12-31 | 10-Q | -260,800,000 | 1,141,752,000 | 1,069,792,000 | ||
| 2024-09-30 | 10-Q | -84,345,000 | -1.28 | 1,188,858,000 | 1,121,126,000 | |
| 2024-06-30 | 10-Q | -57,166,000 | -0.88 | 675,230,000 | 637,038,000 | |
| 2024-03-31 | 10-Q | -44,482,000 | -0.69 | 708,466,000 | 675,039,000 | |
| 2023-12-31 | 10-Q | -126,200,000 | 732,384,000 | 700,561,000 | ||
| 2023-12-31 | 10-K | -126,219,000 | -2.17 | 732,384,000 | 700,561,000 | |
| 2023-09-30 | 10-Q | -33,645,000 | -0.59 | 425,080,000 | 395,977,000 | |
| 2023-06-30 | 10-Q | -29,090,000 | -0.51 | 441,948,000 | 421,153,000 | |
| 2023-03-31 | 10-Q | -25,192,000 | -0.44 | 460,989,000 | 443,968,000 | |
| 2022-12-31 | 10-Q | -81,900,000 | 482,459,000 | 462,978,000 | ||
| 2022-12-31 | 10-K | -81,854,000 | -1.65 | 482,459,000 | 462,978,000 | |
| 2022-09-30 | 10-Q | -19,716,000 | -0.41 | 249,558,000 | 236,583,000 | |
| 2022-06-30 | 10-Q | -18,466,000 | -0.38 | 263,021,000 | 252,985,000 | |
| 2022-03-31 | 10-Q | -17,549,000 | -0.36 | 277,039,000 | 268,915,000 | |
| 2021-12-31 | 10-Q | -46,300,000 | 293,824,000 | 285,037,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-09 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -900 | 105.00 | -94,500.00 | -13,7% | |
| 2026-04-09 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -2,193 | 104.27 | -228,664.11 | -33,2% | |
| 2026-04-01 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -3,544 | 104.39 | -369,958.16 | -53,7% | |
| 2026-04-01 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -2,469 | 106.18 | -262,158.42 | -38,0% | |
| 2026-04-01 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -5,417 | 105.30 | -570,410.10 | -82,8% | |
| 2026-03-26 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -1,757 | 98.21 | -172,554.97 | -25,0% | |
| 2026-03-26 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -940 | 97.50 | -91,650.00 | -13,3% | |
| 2026-03-26 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -2,803 | 99.46 | -278,786.38 | -40,5% | |
| 2026-03-13 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -1,703 | 99.71 | -169,806.13 | -24,6% | |
| 2026-03-13 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -2,597 | 98.83 | -256,661.51 | -37,2% | |
| 2026-03-13 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -804 | 97.89 | -78,703.56 | -11,4% | |
| 2026-03-12 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -5,505 | 98.44 | -541,912.20 | -78,6% | |
| 2026-03-12 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -24,189 | 97.79 | -2,365,442.31 | -343,2% | |
| 2026-03-12 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -306 | 99.12 | -30,330.72 | -4,4% | |
| 2026-02-26 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -2,602 | 103.41 | -269,072.82 | -39,0% | |
| 2026-02-26 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -2,698 | 102.64 | -276,922.72 | -40,2% | |
| 2026-02-26 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -200 | 103.96 | -20,792.00 | -3,0% | |
| 2026-01-22 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -14,300 | 110.16 | -1,575,288.00 | -228,6% | |
| 2026-01-21 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -700 | 109.84 | -76,888.00 | -11,2% | |
| 2026-01-06 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -1,369 | 97.33 | -133,244.77 | -19,3% | |
| 2026-01-06 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -189 | 98.40 | -18,597.60 | -2,7% | |
| 2026-01-06 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -225 | 98.40 | -22,140.00 | -3,2% | |
| 2026-01-06 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,635 | 97.33 | -159,134.55 | -23,1% | |
| 2026-01-06 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,321 | 96.75 | -127,806.75 | -18,5% | |
| 2026-01-06 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -1,331 | 97.33 | -129,546.23 | -18,8% | |
| 2026-01-06 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -1,075 | 96.75 | -104,006.25 | -15,1% | |
| 2026-01-06 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -183 | 98.40 | -18,007.20 | -2,6% | |
| 2026-01-06 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -1,106 | 96.75 | -107,005.50 | -15,5% | |
| 2026-01-05 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -1,137 | 97.96 | -111,380.52 | -16,2% | |
| 2026-01-05 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -1,987 | 97.96 | -194,646.52 | -28,2% | |
| 2026-01-05 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -1,153 | 96.85 | -111,668.05 | -16,2% | |
| 2026-01-05 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -897 | 96.06 | -86,165.82 | -12,5% | |
| 2026-01-05 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -326 | 98.52 | -32,117.52 | -4,7% | |
| 2026-01-05 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -660 | 96.85 | -63,921.00 | -9,3% | |
| 2026-01-05 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -513 | 96.06 | -49,278.78 | -7,2% | |
| 2026-01-05 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -186 | 98.52 | -18,324.72 | -2,7% | |
| 2026-01-05 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,929 | 97.96 | -188,964.84 | -27,4% | |
| 2026-01-05 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,119 | 96.85 | -108,375.15 | -15,7% | |
| 2026-01-05 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -871 | 96.06 | -83,668.26 | -12,1% | |
| 2026-01-05 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -317 | 98.52 | -31,230.84 | -4,5% | |
| 2026-01-02 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -4,005 | 100.03 | -400,620.15 | -58,1% | |
| 2026-01-02 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -540 | 101.47 | -54,793.80 | -8,0% | |
| 2026-01-02 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -5,455 | 100.77 | -549,700.35 | -79,8% | |
| 2025-12-08 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -100 | 111.32 | -11,132.00 | -1,6% | |
| 2025-12-08 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -6,984 | 110.31 | -770,405.04 | -111,8% | |
| 2025-11-24 | Flynn James E | Director, 10% Owner | Open Market Sale | -371,287 | 95.45 | -35,437,487.72 | -5142,1% | |
| 2025-11-18 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -220 | 103.61 | -22,794.20 | -3,3% | |
| 2025-11-18 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -509 | 104.54 | -53,210.86 | -7,7% | |
| 2025-11-17 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -3,609 | 93.80 | -338,524.20 | -49,1% | |
| 2025-11-17 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -380 | 103.68 | -39,398.40 | -5,7% | |
| 2025-11-17 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -3,194 | 102.13 | -326,203.22 | -47,3% | |
| 2025-11-17 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -3,266 | 95.12 | -310,661.92 | -45,1% | |
| 2025-11-17 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -4,496 | 100.58 | -452,207.68 | -65,6% | |
| 2025-11-17 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -5,055 | 103.27 | -522,029.85 | -75,7% | |
| 2025-11-17 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -608 | 107.04 | -65,080.32 | -9,4% | |
| 2025-11-17 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -8,517 | 105.98 | -902,631.66 | -131,0% | |
| 2025-11-17 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -15,075 | 105.16 | -1,585,287.00 | -230,0% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -500 | 99.66 | -49,830.00 | -7,2% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -9,382 | 104.78 | -983,045.96 | -142,6% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -3,733 | 102.88 | -384,051.04 | -55,7% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -2,121 | 102.00 | -216,342.00 | -31,4% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -3,491 | 103.90 | -362,714.90 | -52,6% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -1,273 | 97.98 | -124,728.54 | -18,1% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -700 | 96.65 | -67,655.00 | -9,8% | |
| 2025-10-30 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -600 | 100.96 | -60,576.00 | -8,8% | |
| 2025-10-20 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -5,000 | 94.91 | -474,550.00 | -68,9% | |
| 2025-10-16 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -4,900 | 92.50 | -453,250.00 | -65,8% | |
| 2025-10-16 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -5,199 | 91.37 | -475,032.63 | -68,9% | |
| 2025-10-16 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -2,277 | 90.54 | -206,159.58 | -29,9% | |
| 2025-10-15 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -14,205 | 90.04 | -1,279,018.20 | -185,6% | |
| 2025-10-15 | Miller Deborah Ann | Officer, Chief Legal Officer | Open Market Sale | -15,624 | 89.98 | -1,405,847.52 | -204,0% | |
| 2025-10-15 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,683 | 85.57 | -144,014.31 | -20,9% | |
| 2025-10-14 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -5,820 | 86.63 | -504,186.60 | -73,2% | |
| 2025-10-14 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -200 | 88.90 | -17,780.00 | -2,6% | |
| 2025-10-14 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -1,167 | 84.98 | -99,171.66 | -14,4% | |
| 2025-10-14 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -866 | 86.11 | -74,571.26 | -10,8% | |
| 2025-10-14 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -400 | 87.39 | -34,956.00 | -5,1% | |
| 2025-10-14 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -12,280 | 85.75 | -1,053,010.00 | -152,8% | |
| 2025-10-14 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,700 | 87.67 | -149,039.00 | -21,6% | |
| 2025-10-13 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -7,637 | 89.81 | -685,878.97 | -99,5% | |
| 2025-10-13 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -12,266 | 88.73 | -1,088,362.18 | -157,9% | |
| 2025-10-13 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -6,138 | 87.90 | -539,530.20 | -78,3% | |
| 2025-10-13 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,596 | 89.22 | -142,395.12 | -20,7% | |
| 2025-10-01 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -19,030 | 85.43 | -1,625,732.90 | -235,9% | |
| 2025-10-01 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -970 | 86.37 | -83,778.90 | -12,2% | |
| 2025-09-30 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -20,000 | 85.06 | -1,701,200.00 | -246,8% | |
| 2025-09-29 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -7,588 | 85.01 | -645,055.88 | -93,6% | |
| 2025-09-10 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -3,725 | 78.83 | -293,641.75 | -42,6% | |
| 2025-08-25 | Noci Darlene | Officer, Chief Development Officer | Open Market Sale | -1,348 | 73.96 | -99,698.08 | -14,5% | |
| 2025-08-25 | Noci Darlene | Officer, Chief Development Officer | Open Market Sale | -2,543 | 74.93 | -190,546.99 | -27,6% | |
| 2025-08-25 | Noci Darlene | Officer, Chief Development Officer | Open Market Sale | -109 | 75.63 | -8,243.67 | -1,2% | |
| 2025-08-15 | Porter James Richard | Director, Officer, President and CEO | Open Market Sale | -6,865 | 75.98 | -521,602.70 | -75,7% | |
| 2025-08-15 | Porter James Richard | Director, Officer, President and CEO | Open Market Sale | -20,035 | 75.22 | -1,507,032.70 | -218,7% | |
| 2025-08-15 | Porter James Richard | Director, Officer, President and CEO | Open Market Sale | -100 | 76.90 | -7,690.00 | -1,1% | |
| 2025-08-07 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -5,500 | 74.85 | -411,675.00 | -59,7% | |
| 2025-07-16 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -14,700 | 85.10 | -1,250,970.00 | -181,5% | |
| 2025-07-15 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -54 | 85.48 | -4,615.92 | -0,7% | |
| 2025-07-15 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -2,484 | 82.67 | -205,352.28 | -29,8% | |
| 2025-07-15 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -1,888 | 83.87 | -158,346.56 | -23,0% | |
| 2025-07-15 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -874 | 84.91 | -74,211.34 | -10,8% | |
| 2025-07-10 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -240 | 80.92 | -19,420.80 | -2,8% | |
| 2025-07-10 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -5,260 | 79.94 | -420,484.40 | -61,0% | |
| 2025-07-09 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -1,945 | 81.08 | -157,700.60 | -22,9% | |
| 2025-07-09 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -200 | 81.90 | -16,380.00 | -2,4% | |
| 2025-06-27 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -2,170 | 79.92 | -173,426.40 | -25,2% | |
| 2025-06-27 | Balcom Alexandra | Officer, Chief Financial Officer | Open Market Sale | -20,000 | 80.02 | -1,600,400.00 | -232,2% | |
| 2025-06-25 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -8,630 | 79.87 | -689,278.10 | -100,0% | |
| 2025-06-06 | Pelish Henry E. | Officer, Chief Scientific Officer | Open Market Sale | -200 | 79.82 | -15,964.00 | -2,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.